GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Inclusion Criteria

• •Age ≥18 years and ≤75 years;
• •ECOG physical condition score: 0\~1;
• •Histologically or cytologically confirmed advanced biliary tract carcinoma (including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma);
• •Preoperative imaging assessment of the disease stage was III/IV;
• •At least one measurable lesion (according to mRECIST criteria)
• •Child-Pugh classification : A or B
• •The main organs function well, and the examination indicators meet the following requirements:
• •Routine blood tests: Hemoglobin ≥90 g/L (no blood transfusion within 14 days);Neutrophil count ≥1.5×10\^9/L; Platelet count ≥80×10\^9/L;
• •Biochemical examination: Total bilirubin ≤2×ULN (upper normal value); ALT or AST ≤ 2.5×ULN; Endogenous creatinine clearance ≥ 50 mL /min (Cockcroft-Gault formula);
• •thyroid function:Thyroid function is normal, thyroid stimulating hormone TSH is defined to be within the normal range. If baseline TSH is outside the normal range, T3 and T4 can be included if they are within the normal range;
• •Myocardial enzyme profile:The myocardial enzyme profile was in the normal range (if simple laboratory abnormalities that were not clinically significant as determined by the investigators could also be included);
• •Estimated survival time ≥ 3 months;
• •Sign the informed consent voluntarily;
• •Good compliance, and family members willing to cooperate with follow-up.